Loading...
XNASTELA
Market cap114mUSD
Jan 03, Last price  
2.91USD
1D
1.04%
1Q
7.78%
IPO
-77.35%
Name

TELA Bio Inc

Chart & Performance

D1W1MN
XNAS:TELA chart
P/E
—
P/S
1.96
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
28.66%
Rev. gr., 5y
47.85%
Revenues
58m
+41.13%
4,245,0008,274,00015,446,00018,213,00029,463,00041,418,00058,453,000
Net income
-47m
L+5.25%
-21,334,000-21,092,000-25,803,000-31,878,000-36,110,000-44,337,000-46,664,000
CFO
-41m
L+0.27%
-16,368,000-19,924,000-25,523,000-24,456,000-30,432,000-40,748,000-40,857,000
Earnings
Mar 19, 2025

Profile

TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. It provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. The company markets its products through a single direct sales force, principally in the United States. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
URL
http://www.telabio.com/
IPO date
Nov 08, 2019
Employees
173
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑12
Income
Revenues
58,453
41.13%
41,418
40.58%
Cost of revenue
102,528
80,425
Unusual Expense (Income)
NOPBT
(44,075)
(39,007)
NOPBT Margin
Operating Taxes
41
Tax Rate
NOPAT
(44,075)
(39,048)
Net income
(46,664)
5.25%
(44,337)
22.78%
Dividends
Dividend yield
Proceeds from repurchase of equity
46,341
34,312
BB yield
-30.61%
-18.34%
Debt
Debt current
565
340
Long-term debt
41,080
40,256
Deferred revenue
Other long-term liabilities
1,685
1,231
Net debt
(5,084)
(1,423)
Cash flow
Cash from operating activities
(40,857)
(40,748)
CAPEX
(611)
(1,872)
Cash from investing activities
(599)
(1,872)
Cash from financing activities
46,267
40,852
FCF
(45,334)
(44,587)
Balance
Cash
46,729
42,019
Long term investments
Excess cash
43,806
39,948
Stockholders' equity
(320,774)
(274,056)
Invested Capital
382,420
329,848
ROIC
ROCE
EV
Common stock shares outstanding
22,869
16,268
Price
6.62
-42.43%
11.50
-10.16%
Market cap
151,391
-19.08%
187,078
0.98%
EV
146,307
185,655
EBITDA
(43,267)
(37,820)
EV/EBITDA
Interest
5,223
4,051
Interest/NOPBT